Shopping Cart
- Remove All
- Your shopping cart is currently empty
BMT-090605 is a potent, selective AAK1 inhibitor with an IC50 of 0.6 nM, and inhibits BMP-2-inducible protein kinase (BIKE) and Cyclin G-associated kinase (GAK) with IC50s of 45 and 60 nM, respectively[1]. BMT-090605 also exhibits antinociceptive activity.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $2,120 | 8-10 weeks | |
50 mg | $2,780 | 8-10 weeks | |
100 mg | $3,700 | 8-10 weeks |
Description | BMT-090605 is a potent, selective AAK1 inhibitor with an IC50 of 0.6 nM, and inhibits BMP-2-inducible protein kinase (BIKE) and Cyclin G-associated kinase (GAK) with IC50s of 45 and 60 nM, respectively[1]. BMT-090605 also exhibits antinociceptive activity. |
In vitro | BMT-090605 shows a cellular IC50 of 0.63 ±0.39 nM for AAK1[1]. |
In vivo | BMT-090605 (0.3-3 μg/rat; intrathecally at lumbar level L5/L6) causes antinociception by inhibiting AAK1 in the spinal cord[1]. Exposure measurements from this study indicated that brain and plasma levels of BMT-090605 were <4 nM, whereas measurable levels (90–317 nM) were observed in lumbar spinal cord[1]. The high dose of BMT-090605 (3 μg/rat) showed efficacy comparable to intrathecal clonidine (3 μg/rat). |
Molecular Weight | 364.44 |
Formula | C21H24N4O2 |
Cas No. | 1551403-51-0 |
Relative Density. | 1.24 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.